Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncternal Therapeutics Inc ONCT

Healthcare Biotechnology
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of... see more

Recent & Breaking News (NDAQ:ONCT)

GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results

Business Wire November 14, 2017

34 Biggest Movers From Yesterday

Benzinga.com  November 14, 2017

GTx, Inc. to Participate in the Stifel 2017 Healthcare Conference

Business Wire November 8, 2017

GTx Announces Closing of $48.5 Million Private Placement

Business Wire September 29, 2017

GTx Announces $48.5 Million Private Placement

Business Wire September 26, 2017

GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference

Business Wire September 25, 2017

GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City

Business Wire September 21, 2017

GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence

Business Wire September 13, 2017

GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results

Business Wire August 14, 2017

GTx Discusses Key Goals with WSA

MarketWire Canada July 12, 2017

22 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  June 30, 2017

12 Biggest Mid-Day Losers For Tuesday

Benzinga.com  June 13, 2017

25 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  June 13, 2017

Mid-Afternoon Market Update: Coherus Biosciences Drops After FDA Response Letter; TrovaGene Shares Surge

Benzinga.com  June 12, 2017

15 Biggest Mid-Day Gainers For Monday

Benzinga.com  June 12, 2017

Mid-Morning Market Update: Markets Open Lower; General Electric CEO To Step Down

Benzinga.com  June 12, 2017

22 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  June 12, 2017

GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence

Business Wire June 12, 2017

GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results

Business Wire May 15, 2017

GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting

Business Wire May 11, 2017